Clinical

Dataset Information

0

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma


ABSTRACT: The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 (a PD-L1/CTLA-4 targeted bispecific antibody).

DISEASE(S): Her2-positive Colorectal Cancer,Biliary Tract Neoplasms,Colorectal Neoplasms,Her2-positive Biliary Tract Cancer

PROVIDER: 70605 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-03-27 | GSE233893 | GEO
2015-03-01 | E-GEOD-59856 | biostudies-arrayexpress
2018-02-14 | GSE90698 | GEO
| 2303997 | ecrin-mdr-crc
2022-04-20 | GSE180296 | GEO
2018-02-14 | GSE90699 | GEO
2021-05-19 | GSE151442 | GEO
2021-10-13 | GSE177053 | GEO
2015-03-01 | GSE59856 | GEO
2019-12-31 | GSE89216 | GEO